The mpMRI PRECISE score predicts disease progression in patients undergoing active surveillance for prostate cancer

被引：0
|
作者：
Trachsel, Y. [1 ]
Manasseh, G. [2 ]
Violi, N. Vietti [2 ]
Roth, B. [1 ]
Valerio, M. [1 ]
Rakauskas, A. [1 ]
机构：
[1] Ctr Hosp Univ Vaudois CHUV, Dept Urol, Lausanne, Switzerland
[2] Ctr Hosp Univ Vaudois CHUV, Dept Radiol, Lausanne, Switzerland
来源：
EUROPEAN UROLOGY | 2023年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0962
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance
    Nikita Sushentsev
    Leonardo Rundo
    Luis Abrego
    Zonglun Li
    Tatiana Nazarenko
    Anne Y. Warren
    Vincent J. Gnanapragasam
    Evis Sala
    Alexey Zaikin
    Tristan Barrett
    Oleg Blyuss
    European Radiology, 2023, 33 : 3792 - 3800
  • [42] Clinical and Demographic Characteristics Associated With Prostate Cancer Progression in Patients on Active Surveillance
    Iremashvili, Viacheslav
    Soloway, Mark S.
    Rosenberg, Daniel L.
    Manoharan, Murugesan
    JOURNAL OF UROLOGY, 2012, 187 (05): : 1594 - 1599
  • [43] The impact of age on prostate cancer progression and quality of life in active surveillance patients
    Merrick, Gregory S.
    Rohmann, Gabe
    Galbreath, Robert
    Scholl, Whitney
    Fiano, Ryan
    Bennett, Abbey
    Butler, Wayne M.
    Adamovich, Edward
    BJUI COMPASS, 2021, 2 (02): : 86 - 91
  • [44] Preventing clinical progression and need for treatment in patients on active surveillance for prostate cancer
    Goldberg, Hanan
    Klaassen, Zachary
    Chandrasekar, Thenappan
    Fleshner, Neil
    CURRENT OPINION IN UROLOGY, 2018, 28 (01) : 46 - 54
  • [45] Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance?
    Tay, K. J.
    Gupta, R.
    Holtz, J.
    Silverman, R.
    Tsivian, E.
    Schulman, A.
    Moul, J.
    Polascik, T.
    BJU INTERNATIONAL, 2017, 119 : 11 - 12
  • [46] THE PCA3 SCORE ACCURATELY PREDICTS TUMOR VOLUME AND MIGHT HELP IN SELECTING PROSTATE CANCER PATIENTS FOR ACTIVE SURVEILLANCE
    Ploussard, G.
    Durand, X.
    Xylinas, E.
    Moutereau, S.
    Radulescu, C.
    Forgue, A.
    Terry, S.
    Allory, Y.
    Loric, S.
    Salomon, L.
    Vacherot, F.
    De La Taille, A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 313 - 314
  • [47] Identification of fluorescence in situ hybridization assay markers for prediction of disease progression in prostate cancer patients on active surveillance
    Katerina Pestova
    Adam J. Koch
    Charles P. Quesenberry
    Jun Shan
    Ying Zhang
    Amethyst D. Leimpeter
    Beth Blondin
    Svetlana Sitailo
    Lela Buckingham
    Jing Du
    Huixin Fei
    Stephen K. Van Den Eeden
    BMC Cancer, 18
  • [48] Identification of fluorescence in situ hybridization assay markers for prediction of disease progression in prostate cancer patients on active surveillance
    Pestova, Katerina
    Koch, Adam J.
    Quesenberry, Charles P.
    Shan, Jun
    Zhang, Ying
    Leimpeter, Amethyst D.
    Blondin, Beth
    Sitailo, Svetlana
    Buckingham, Lela
    Du, Jing
    Fei, Huixin
    Van den Eeden, Stephen K.
    BMC CANCER, 2018, 18
  • [49] A randomized study of enzalutamide in patients with localized prostate cancer undergoing active surveillance (ENACT).
    Shore, Neal D.
    Vourganti, Srinivas
    Silberstein, Jonathan L.
    Brown, Bruce A.
    Wilson, Samuel
    Hollowell, Courtney M. P.
    Cooperberg, Matthew
    Shang, Gwendoline
    Fleshner, Neil Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Incidence of Reclassification in Patients Undergoing Active Surveillance for Favorable-Risk Prostate Cancer
    Kim, J.
    Davis, J. W.
    Ward, J.
    Wang, X.
    Pettaway, C.
    Pisters, L.
    Matin, S.
    Kuban, D.
    Frank, S. J.
    Lee, A. K.
    Prokhorova, I. N.
    Brown, V. T.
    Logothetis, C. J.
    Troncoso, P.
    LABORATORY INVESTIGATION, 2011, 91 : 204A - 204A
12345